OBJECTIVE:Low-carbohydrate diets have become a popular alternative to standard diets for weight loss. Our aim was to compare the cost-effectiveness of these two diets. RESEARCH METHODS AND PROCEDURES: The patient population included 129 severely obese subjects (BMI = 42.9) from a randomized trial; participants had a high prevalence of diabetes or metabolic syndrome. We compared within-trial costs, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (CER) for the two study groups. We imputed missing values for QALYs. The CER was bootstrapped to derive 95% confidence intervals and to define acceptability cut-offs. We took a societal perspective for our analysis. RESULTS:Total costs during the one year of the trial were 6742 dollars +/- 6675 and 6249 dollars +/- 5100 for the low-carbohydrate and standard groups, respectively (p = 0.78). Participants experienced 0.64 +/- 0.02 and 0.61 +/- 0.02 QALYs during the one year of the study, respectively (p = 0.17 for difference). The point estimate of the incremental CER was -1225 dollars/QALY (i.e., the low-carbohydrate diet dominated the standard diet). However, in the bootstrap analysis, the wide spread of CERs caused the 95% confidence interval to be undefined. The probabilities that the low-carbohydrate diet was acceptable, using cut-offs of 50,000 dollars/QALY, 100,000 dollars/QALY, and 150,000 dollars/QALY, were 72.4% 78.6%, and 79.8%, respectively. DISCUSSION: The low-carbohydrate diet was not more cost-effective for weight loss than the standard diet in the patient population studied. Larger studies are needed to better assess the cost-effectiveness of dietary therapies for weight loss.
RCT Entities:
OBJECTIVE: Low-carbohydrate diets have become a popular alternative to standard diets for weight loss. Our aim was to compare the cost-effectiveness of these two diets. RESEARCH METHODS AND PROCEDURES: The patient population included 129 severely obese subjects (BMI = 42.9) from a randomized trial; participants had a high prevalence of diabetes or metabolic syndrome. We compared within-trial costs, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (CER) for the two study groups. We imputed missing values for QALYs. The CER was bootstrapped to derive 95% confidence intervals and to define acceptability cut-offs. We took a societal perspective for our analysis. RESULTS: Total costs during the one year of the trial were 6742 dollars +/- 6675 and 6249 dollars +/- 5100 for the low-carbohydrate and standard groups, respectively (p = 0.78). Participants experienced 0.64 +/- 0.02 and 0.61 +/- 0.02 QALYs during the one year of the study, respectively (p = 0.17 for difference). The point estimate of the incremental CER was -1225 dollars/QALY (i.e., the low-carbohydrate diet dominated the standard diet). However, in the bootstrap analysis, the wide spread of CERs caused the 95% confidence interval to be undefined. The probabilities that the low-carbohydrate diet was acceptable, using cut-offs of 50,000 dollars/QALY, 100,000 dollars/QALY, and 150,000 dollars/QALY, were 72.4% 78.6%, and 79.8%, respectively. DISCUSSION: The low-carbohydrate diet was not more cost-effective for weight loss than the standard diet in the patient population studied. Larger studies are needed to better assess the cost-effectiveness of dietary therapies for weight loss.
Authors: Michael G Perri; Aviva H Ariel-Donges; Meena N Shankar; Marian C Limacher; Michael J Daniels; David M Janicke; Kathryn M Ross; Linda B Bobroff; A Daniel Martin; Tiffany A Radcliff; Christie A Befort Journal: Contemp Clin Trials Date: 2018-11-06 Impact factor: 2.226
Authors: A G Tsai; T A Wadden; S Volger; D B Sarwer; M Vetter; S Kumanyika; R I Berkowitz; L K Diewald; J Perez; J Lavenberg; E R Panigrahi; H A Glick Journal: Int J Obes (Lond) Date: 2013-08 Impact factor: 5.095
Authors: Mark A Espeland; Henry A Glick; Alain Bertoni; Frederick L Brancati; George A Bray; Jeanne M Clark; Jeffrey M Curtis; Caitlin Egan; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Helen P Hazuda; James O Hill; Don Hire; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Tina Killean; Abbas E Kitabchi; William C Knowler; Andrea Kriska; Cora E Lewis; Marsha Miller; Maria G Montez; Anne Murillo; David M Nathan; Ebenezer Nyenwe; Jennifer Patricio; Anne L Peters; Xavier Pi-Sunyer; Henry Pownall; J Bruce Redmon; Julia Rushing; Donna H Ryan; Monika Safford; Adam G Tsai; Thomas A Wadden; Rena R Wing; Susan Z Yanovski; Ping Zhang Journal: Diabetes Care Date: 2014-09 Impact factor: 19.112
Authors: Nicholas Graves; Adrian G Barnett; Kate A Halton; Jacob L Veerman; Elisabeth Winkler; Neville Owen; Marina M Reeves; Alison Marshall; Elizabeth Eakin Journal: PLoS One Date: 2009-09-25 Impact factor: 3.240
Authors: D Boyers; L Retat; E Jacobsen; A Avenell; P Aveyard; E Corbould; A Jaccard; D Cooper; C Robertson; M Aceves-Martins; B Xu; Z Skea; M de Bruin Journal: Int J Obes (Lond) Date: 2021-06-04 Impact factor: 5.095